Drug Formulation Advances in Extended-Release Medications for Pain Control.

about

A Brief History of the Opioid Epidemic and Strategies for Pain Medicine.

P2860

Q52565263-F69FF886-26E1-4932-806B-5846A430B00B

P2860

Drug Formulation Advances in Extended-Release Medications for Pain Control.

Item

http://www.wikidata.org/entity/Q38809652

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Drug Formulation Advances in Extended-Release Medications for Pain Control.

@en

type

Item

label

Drug Formulation Advances in Extended-Release Medications for Pain Control.

@en

prefLabel

Drug Formulation Advances in Extended-Release Medications for Pain Control.

@en

P1476

Drug Formulation Advances in Extended-Release Medications for Pain Control

@en

P2093

Alan D Kaye

http://www.w3.org/2001/XMLSchema#string

Amit Prabhakar

http://www.w3.org/2001/XMLSchema#string

Martin J Carney

http://www.w3.org/2001/XMLSchema#string

Rachel J Kaye

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.

Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.

The pharmacological basis of contemporary pain management.

Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study

Prescription opioid abuse: a literature review of the clinical and economic burden in the United States.

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.

A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study

Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain

P2888

s11916-016-0565-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11916-016-0565-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mark R Jones

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027983977

http://www.w3.org/2001/XMLSchema#string

P698

27084375

http://www.w3.org/2001/XMLSchema#string

Drug Formulation Advances in Extended-Release Medications for Pain Control.

about

P2860

P2860

Drug Formulation Advances in Extended-Release Medications for Pain Control.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698